Eagle Pharmaceuticals Inc. filed three new federal lawsuits seeking lost profits for its Belrapzo leukemia drug and alleging branded copies made by Apotex Inc., Slayback Pharma LLC, and Baxter Healthcare Corp. infringe two patents issued in the past month.
The complaints, docketed Thursday in the US District Court for the District of Delaware, were filed Wednesday—one day after the Federal Circuit upheld an October 2022 district court decision that found Slayback and Apotex’s drugs didn’t infringe a different Belrapzo patent. Eagle also seeks royalties and orders blocking sales of the targeted drugs until the patents have expired.
Eagle alleges that ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.